Global Market Study on Dermatophytic Onychomycosis Therapeutics (DOT): North America Expected to Account for Maximum Market Share by 2021, Due to Increasing Prevalence of Fungal Toe Nail Infections


  • Published On : Jan-2016 |
  • Pages : 183 Pages |
  • Format :

Dermatophytic onychomycosis is a fungal nail infection caused by dermatophytes. Dermatophytic onychomycosis is also known as tinea unguium. It is called the dermatophytic invasion of the nail plate. It is the most common nail infection and constitutes more than half of all nail disease cases. This condition mostly affects toenails. The overall prevalence rate of dermatophytic onychomycosis is around 10% in the general population. The disease can lead to severe pain and can impede work and social activities.

This report covers the global dermatophytic onychomycosis therapeutics market performance in terms of revenue contribution. The report includes key trends, drivers, restraints, and opportunities influencing the growth of the global dermatophytic onychomycosis therapeutics market. Impact analysis of key growth drivers and restraints, based on the weighted average model, are included to better equip clients with crystal clear decision-making insights.

The global dermatophytic onychomycosis therapeutics market is mainly driven by factors such as increasing the prevalence of dermatophytic onychomycosis, rising aging population, increasing consumer inclination towards maintaining aesthetic appearance of nails, and increasing per capita healthcare expenditure. Potential side effects of therapeutic products, availability of alternative treatments, and lack of awareness in emerging regions such as APEJ and MEA are expected to hinder the growth of the dermatophytic onychomycosis therapeutics market.

On the basis of products, dermatophytic onychomycosis therapeutics market is segmented into tablet and nail paint. Both the segments, tablet and nail paint are further sub-segmented into prescription and over-the-counter products. By distribution channel, dermatophytic onychomycosis therapeutics market is segmented into hospitals, clinics, independent pharmacies, mail order pharmacies, and drug stores.

By product, revenue from the tablet segment is projected to rise at the highest CAGR of 5.2% during the forecast period. The nail paint segment is expected to dominate the market, accounting for a maximum share of the overall market by 2021. The nail paint segment revenue is projected to rise at a CAGR of 8.3% during the forecast period (2015–2021).

By treatment, the topical segment is estimated to dominate the dermatophytic onychomycosis therapeutics market, accounting for a maximum share of the overall market by 2015 end. Revenue from the topical segment is projected to increase at a CAGR of 8.3% during the forecast period.

In terms of value, North America dominated the market with over 43% market share in 2014, followed by Europe. In Asia Pacific, this market is projected to expand at the highest CAGR of 5.1% during the forecast period.

The dermatophytic onychomycosis therapeutics market is segmented as follows:

By Product:

  • Tablet
    • Prescription (Rx.)
    • Over-the-counter
  • Nail Paint
    • Prescription (Rx.)
    • Over-the-counter

By Treatment:

  • Oral
  • Topical

By Distribution Channels:

  • Hospitals
  • Clinics
  • Independent Pharmacies
  • Mail Order Pharmacies
  • Drug Stores

By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • Italy
    • France
    • U.K.
    • Spain
    • Rest of Europe
  • Asia pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Argentina
    • Rest of Latin America
  • MEA
    • GCC Nations
    • South Africa
    • Rest of MEA

Key features included in this report:

  • Drivers and restraints of the dermatophytic onychomycosis therapeutics market
  • Latest product innovations and key developments in the market
  • Analysis of business strategies of the top players
  • Dermatophytic onychomycosis therapeutics market estimates and forecasts

Dermatophytic onychomycosis is a fungal infection of nail caused by dermatophytes. It makes the nails look white and opaque, thickened, and brittle. People in the age group of 60-65 years with diabetes or disease of the small blood vessels (peripheral vascular disease) are at increased risk. Dermatophytic onychomycosis therapeutics market consists of drugs used for a treatment of the disease.

The global dermatophytic onychomycosis therapeutics market was valued at US$ 2,870 Mn in 2014. North America was the largest market for dermatophytic onychomycosis therapeutics, accounting for over 43% revenue share of the overall market in 2014, followed by Europe with around 28% share. North America market is expected to exhibit the highest CAGR of 9.2% during the forecast period (2015–2021), followed by Europe. Factors such as increasing per capita healthcare spending, rising aging population, consumers’ disposition towards maintaining aesthetic appearing nails, and growing product innovation are expected to support the growth of the dermatophytic onychomycosis therapeutics market during the forecast period.

The global dermatophytic onychomycosis therapeutics market is projected to be valued at US$ 3,057.8 Mn by the end of 2015 and is further expected to reach US$ 4,706.3 Mn by the end of 2021, at a CAGR of 7.5%.

By product, the nail paint segment accounted for about 70% share of overall market value in 2014. By treatment, the oral segment was valued at US$ 861 Mn in 2014 and is expected to increase at a CAGR of 5.2% during the forecast period to account for US$ 1,221.9 Mn by 2021. By distribution channels, the drug store segment contributed the highest revenue of US$ 1,343.2 Mn, accounting for approximately 47% market share in 2014. Independent pharmacies were the second-largest segment by distribution channel, accounting for about 20% revenue share in 2014.

Key players of the global dermatophytic onychomycosis therapeutics market include Valeant Pharmaceuticals International Inc., Galderma S.A., Novartis AG, Pfizer Inc., Moberg Pharma AB, Johnson & Johnson Services, Inc., and Anacor Pharmaceuticals, Inc.

dermatophytic-onychomycosis-therapeutics-market

Key players of the global dermatophytic onychomycosis therapeutics market:

  • Valeant Pharmaceuticals International Inc.
  • Galderma S.A.
  • Novartis AG, Pfizer Inc.
  • Moberg Pharma AB.
  • Johnson & Johnson Services, Inc.
  • Anacor Pharmaceuticals, Inc.
  • Other.

Leading players operating in the market collaborate with healthcare solutions and services providers in order to advance operational efficiencies and provide improved patient care.

Back To Top